Loading
A US study asking whether pairing the Galleri blood test with tracking of unexplained weight loss finds cancers earlier in people losing weight without trying.
Galleri with weight tracking in unintentional weight loss (NCT05481697) is a single-arm interventional study sponsored by Case Comprehensive Cancer Center with University Hospitals Seidman Cancer Center. Its primary outcome is the detection of cancers causing unintentional weight loss.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,000 participants, a start on 5 May 2023 and primary completion expected on 1 January 2027.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/